Are you getting the attention you need from your current central lab?

Barc Lab aspires to partner with you to develop bespoke, optimized solutions for your projects to ensure success of your treatments and improve patients’ lives. With more than 35 years of experience, 375 ongoing clinical trials, and divisions in 5 continents, we have the expertise, scientific knowledge, and technology needed to help you achieve your goals. 

THERAPEUTIC AREAS

We can meet you anywhere to deliver a unique plan for any of these key therapeutic areas, and support clients in every step of their clinical trials.

Our mission is to partner with you to bring personalized medicine to patients and
allow you to focus on what matters most: Improving healthcare and quality of life.

Oncology

As a global leader in oncology trials, we can keep you on track and beyond in this ever-evolving field.

NASH

We support the biggest phase 3 study in NASH so far, in search of a better diagnosis and treatment.

Infectious diseases

We offer flexible assays, fast and secure diagnostic opportunities, and can react quickly to new
infectious threats with the development of new tests.

Inflammatory disorders

Our specialists are committed to help you determine which tests could be implemented making your
study in inflammatory disorders more informative and less risky.

We can provide you with the solution you need by tapping on to our broad testing portfolio, ranging from Flow Cytometry, Histopathology, PK and Biomarker testing, NGS, Microbiology and any other esoteric & routing testing.

Learn more

Go to article: Home | The deep dive for new drugsGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Hapa Company InsightGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Owen MumfordGo to article: The pharma industry briefingGo to article: Capsugel Company InsightGo to article: Swiss WorldCargoGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Underwater forests and the search for natures’ next drug treasure troveGo to article: Barc Lab Go to article: BEAGo to article: Developing drugs for NASH: the race to market Go to article: SmartCAE Company InsightGo to article: SmartCAEGo to article: Zulresso: the world’s first post-partum depression drugGo to article: EcocoolGo to article: Moehs Iberica SLGo to article: Predicting drug flops with AIGo to article: Abiogen PharmaGo to article: LaudaGo to article: Proteomics and the promise of ‘enriching’ clinical trials Go to article: Lubrizol Life SciencesGo to article: SkycellGo to article: EventsGo to article: TemptimeGo to article: Next issueGo to article: Pfanstiehl Company InsightGo to article: Pfanstiehl